Graduate University of Chinese Academy of Sciences, 19 Yuquan Road, Shijingshan District, Beijing 100049, China.
ChemMedChem. 2010 Jun 7;5(6):890-8. doi: 10.1002/cmdc.201000042.
Unsymmetrical phthalocyanine derivatives have been widely studied as photosensitizers for photodynamic therapy (PDT), targeting various tumor types. However, the preparation of unsymmetrical phthalocyanines is always a challenge due to the presence of many possible structural isomers. Herein we report a new unsymmetrical zinc phthalocyanine, pentalysine beta-carbonylphthalocyanine zinc (ZnPc-(Lys)(5)), that was prepared in large quantity and high purity. This is a water-soluble cationic photosensitizer and maintains a high quantum yield of singlet oxygen generation similar to that of unsubstituted zinc phthalocyanine (ZnPc). Compared with anionic ZnPc counterparts, ZnPc-(Lys)(5) shows a higher level cellular uptake and 20-fold higher phototoxicity toward tumor cells. Pharmacokinetics and PDT studies of ZnPc-(Lys)(5) in S180 tumor-bearing mice showed a high ratio of tumor versus skin retention and significant tumor inhibition. This new molecular framework will allow synthetic diversity in the number of lysine residues incorporated and will facilitate future QSAR studies.
不对称酞菁衍生物已被广泛研究作为光动力疗法(PDT)的光敏剂,针对各种肿瘤类型。然而,由于存在许多可能的结构异构体,不对称酞菁的制备一直是一个挑战。在此,我们报告了一种新的不对称锌酞菁,五赖氨酸β-羰基酞菁锌(ZnPc-(Lys)(5)),其可大量且高纯度制备。这是一种水溶性阳离子光敏剂,其单线态氧生成的量子产率与未取代的锌酞菁(ZnPc)相似。与阴离子 ZnPc 相比,ZnPc-(Lys)(5)对肿瘤细胞的细胞摄取水平更高,光毒性提高了 20 倍。在 S180 荷瘤小鼠中进行的 ZnPc-(Lys)(5)的药代动力学和 PDT 研究表明,肿瘤与皮肤的保留率很高,并且具有显著的肿瘤抑制作用。这种新的分子结构框架将允许在整合的赖氨酸残基数方面进行合成多样性,并将促进未来的定量构效关系研究。